Entropy Neurodynamics Limited (ASX:ENP)
Australia · Delayed Price · Currency is AUD 0.0410
-0.0010 (-2.38%)
Sep 11, 2026, 9:59 AM AEST
Entropy Neurodynamics Revenue
In the fiscal year ending June 30, 2026, Entropy Neurodynamics had annual revenue of 1.91M AUD with 20.53% growth. Entropy Neurodynamics had revenue of 1.91M in the half year ending June 30, 2026.
Revenue
1.91M
Revenue Growth
+20.53%
P/S Ratio
35.11
Revenue / Employee
n/a
Employees
n/a
Market Cap
66.94M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.91M | 324.75K | 20.53% |
| Jun 30, 2025 | 1.58M | 254.43K | 19.17% |
| Jun 30, 2024 | 1.33M | - | - |
| Aug 31, 2023 | - | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 33.80M |
| Immutep | 19.93M |
| Neurizon Therapeutics | 17.59M |
| Radiopharm Theranostics | 13.50M |
| Recce Pharmaceuticals | 9.47M |
| Amplia Therapeutics | 4.79M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |